Data frame containing the results of 50 trials of 8 thrombolytic drugs (streptokinase, SK; alteplase, t-PA; accelerated alteplase, Acc t-PA; streptokinase plus alteplase, SK+tPA; reteplase, r-PA; tenocteplase, TNK; urokinase, UK; anistreptilase, ASPAC) plus per-cutaneous transluminal coronary angioplasty (PTCA) (Boland et al. 2003; Lu and Ades 2006; Dias et al. 2011) . The number of deaths in 30 or 35 days following acute myocardial infarction are recorded.
Format
A data frame with 102 rows and 5 variables:
- studyn
numeric study ID
- trtn
numeric treatment code
- trtc
treatment name
- r
total number of events
- n
total number of individuals
References
Boland A, Dundar Y, Bagust A, Haycox A, Hill R, Mota RM, Walley T, Dickson R (2003).
“Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.”
Health Technology Assessment, 7(15).
doi:10.3310/hta7150
.
Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE (2011).
“NICE DSU Technical Support Document 4: Inconsistency in networks of evidence based on randomised controlled trials.”
National Institute for Health and Care Excellence.
https://www.sheffield.ac.uk/nice-dsu.
Lu GB, Ades AE (2006).
“Assessing evidence inconsistency in mixed treatment comparisons.”
Journal of the American Statistical Association, 101(474), 447--459.
doi:10.1198/016214505000001302
.